Noveris Health Sciences Inc. is trading 14% down at $1.72 today, extending a sharp selloff triggered by governance concerns and a lack of operational progress.
- The decline follows last week's uncertainty surrounding the company's new advisory board chair and a perceived lack of visible clinical or financial milestones.
- The stock's downward trajectory persists despite a broadly positive market backdrop, suggesting that investors are prioritizing company-specific risks over general equity market sentiment.